Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/controlled-release-carvedilol-iTA6FXSyfj
References (82)
-
Hong-hao Zhou, A. Wood (1995)
Stereoselective disposition of carvedilol is determined by CYP2D6Clinical Pharmacology & Therapeutics, 57
-
M. Packer, M. Lukas, D. Tenero, Charlotte Baidoo, B. Greenberg (2006)
Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.The American journal of cardiology, 98 7A
-
M. Komajda, B. Lutiger, H. Madeira, K. Thygesen, M. Bobbio, P. Hildebrandt, W. Jaarsma, G. Riegger, L. Rydén, A. Scherhag, J. Soler‐Soler, W. Remme (2004)
Tolerability of carvedilol and ACE‐Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE‐Inhibitor Remodelling Mild CHF EvaluatioN)European Journal of Heart Failure, 6
-
P. Poole‐Wilson, K. Swedberg, J. Cleland, A. Lenarda, P. Hanrath, M. Komajda, J. Lubsen, B. Lutiger, M. Metra, W. Remme, C. Torp-Pedersen, A. Scherhag, A. Skene (2003)
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trialThe Lancet, 362
-
H. Why, P. Richardson (1992)
Effect of carvedilol on left ventricular function and mass in hypertension.Journal of cardiovascular pharmacology, 19 Suppl 1
-
G. Fonarow (2006)
Profile of carvedilol controlled-release: a new once-daily formulation of carvedilolExpert Opinion on Pharmacotherapy, 7
-
R. Pinals, S. Kaplan, J. Lawson, B. Hepburn (1986)
A double‐blind, placebo‐controlled trialArthritis & Rheumatism, 29
-
M.A. Weber, G.L. Bakris, E.A. Tarka (2006)
Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension [published erratum appears in J Clin Hypertens 2007 Feb; 9 (2): 154]J Clin Hypertens, 8
-
R. Frantz, L. Olson, D. Grill, S. Moualla, Susan Nelson, T. Nobrega, R. Hanna, R. Backes, F. Mookadam, D. Heublein, K. Bailey, J. Burnett (2005)
Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure.American heart journal, 149 3
-
G. Keating, B. Jarvis (2003)
Carvedilol: a review of its use in chronic heart failure.Drugs, 63 16
-
A. Palazzuoli, F. Bruni, L. Puccetti, M. Pastorelli, P. Angori, A. Pasqui, A. Auteri (2002)
Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failureEuropean Journal of Heart Failure, 4
-
C. Sung, A. Arleth, E. Ohlstein (1993)
Carvedilol Inhibits Vascular Smooth Muscle Cell ProliferationJournal of Cardiovascular Pharmacology, 21
-
I. Paraskevaidis, G. Theodorakis, D. Katritsis, D. Tsiapras, E. Livanis, D. Kremastinos (1999)
Pulmonary vein flow analysis by transoesophageal echocardiogr phy in patients with chronic atrial fibrillation; 1 year follow-up after cardioversion.European heart journal, 20 5
-
G. Leonetti, L. Sampieri, C. Cuspidi, L. Boselli, L. Terzoli, L. Rupoli, A. Zanchetti (1987)
Resting and Postexercise Hemodynamic Effects of Carvedilol, a &bgr;‐Adrenergic Blocker and Precapillary Vasodilator in Hypertensive PatientsJournal of Cardiovascular Pharmacology, 10
-
M. Kindermann, C. Maack, S. Schaller, N. Finkler, Kathrin Schmidt, S. Läer, H. Wuttke, H. Schäfers, M. Böhm (2004)
Carvedilol but Not Metoprolol Reduces β-Adrenergic Responsiveness After Complete Elimination From Plasma In VivoCirculation: Journal of the American Heart Association, 109
-
T. Yue, Xinliang Ma, Xinkang Wang, A. Romanic, Gao-lin Liu, C. Louden, J. Gu, Sanjay Kumar, G. Poste, R. Ruffolo, G. Feuerstein (1998)
Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol.Circulation research, 82 2
-
R. Eggertsen, L. Andrén, R. Sivertsson, L. Hansson (2004)
Acute haemodynamic effects of carvedilol (BM 14190), a new combined beta-adrenoceptor blocker and precapillary vasodilating agent, in hypertensive patientsEuropean Journal of Clinical Pharmacology, 27
-
Frencesco Romeo, Dayuan Li, Min Shi, Jawahar Mehta (2000)
Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway.Cardiovascular research, 45 3
-
F. Marchi, G. Ciriello (1995)
Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol.Advances in therapy, 12 4
-
J. Cohn, M. Fowler, M. Bristow, W. Colucci, E. Gilbert, V. Kinhal, S. Krueger, T. LeJemtel, K. Narahara, M. Packer, S. Young, T. Holcslaw, M. Lukas (1997)
Safety and efficacy of carvedilol in severe heart failureJournal of Cardiac Failure, 3
-
R. Boer, H. Siebelink, R. Tio, F. Boomsma, D. Veldhuisen (2001)
Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failureEuropean Journal of Heart Failure, 3
-
H. Eichstaedt, R. Schroeder, W. Auffermann, W. Richter (1992)
Regression of left ventricular hypertrophy.Journal of cardiovascular pharmacology, 19 Suppl 1
-
P. Hauptman, S. Pressler, J. Sackner-Bernstein, P. Ordronneau, J. Udelson (2006)
Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure.The American journal of cardiology, 98 7A
-
G. Bakris, V. Fonseca, R. Katholi, J. McGill, F. Messerli, R. Phillips, P. Raskin, J. Wright, B. Waterhouse, M. Lukas, K. Anderson, D. Bell (2005)
Differential Effects of &bgr;-Blockers on Albuminuria in Patients With Type 2 DiabetesHypertension, 46
-
W. Remme, G. Riegger, P. Hildebrandt, M. Komajda, W. Jaarsma, M. Bobbio, J. Soler‐Soler, A. Scherhag, B. Lutiger, L. Rydén (2004)
The Benefits of Early Combination Treatment of Carvedilol and an ACE-Inhibitor in Mild Heart Failure and Left Ventricular Systolic Dysfunction. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN)Cardiovascular Drugs and Therapy, 18
-
A. Cournot, C. Lim, J. Duchier, M. Safar (1992)
Hemodynamic effects of carvedilol after acute oral administration in hypertensive and normal subjects.Journal of cardiovascular pharmacology, 19 Suppl 1
-
R. Eggertsen, R. Sivertsson, L. Andrén, L. Hansson (1987)
Acute and Long‐Term Hemodynamic Effects of Carvedilol, a Combined &bgr;‐Adrenoceptor Blocking and Precapillary Vasodilating Agent, in Hypertensive PatientsJournal of Cardiovascular Pharmacology, 10
-
M.R. Bristow, E.M. Gilbert, W.T. Abraham (1996)
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failureCirculation, 94
-
D. Giugliano, R. Acampora, R. Marfella, N. Rosa, P. Ziccardi, R. Ragone, L. Angelis, F. D'onofrio (1997)
Metabolic and Cardiovascular Effects of Carvedilol and Atenolol in Non-Insulin-Dependent Diabetes Mellitus and HypertensionAnnals of Internal Medicine, 126
-
M. Packer, W.S. Colucci, J.D. Sackner-Bernstein (1996)
Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trialCirculation, 94
-
Anders Bergström, B. Andersson, M. Edner, E. Nylander, H. Persson, U. Dahlström (2004)
Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler‐echocardiographic study (SWEDIC)European Journal of Heart Failure, 6
-
P. Lund-johansen, P. Omvik (1992)
Chronic haemodynamic effects of carvedilol in essential hypertension at rest and during exercise.European heart journal, 13 2
-
W.S. Colucci, M. Packer, M.R. Bristow (1996)
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failureCirculation, 94
-
M. Guazzi, P. Agostoni, M. Matturri, G. Pontone, M. Guazzi (1999)
Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol.American heart journal, 138 3 Pt 1
-
A. Dupont, Patricia Niepen, Y. Taeymans, M. Ingels, A. Piepsz, A. Bossuyt, P. Block, R. Six, M. Jonckheer, L. Vanhaelst (1987)
Effect of Carvedilol on Ambulatory Blood Pressure, Renal Hemodynamics, and Cardiac Function in Essential HypertensionJournal of Cardiovascular Pharmacology, 10
-
Yutaka Takeda, T. Fukutomi, Shogo Suzuki, Koji Yamamoto, Masaki Ogata, H. Kondo, M. Sugiura, J. Shigeyama, M. Itoh (2004)
Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.The American journal of cardiology, 94 4
-
B. Agrawal, K. Wolf, A. Berger, F. Luft (1996)
Effect of antihypertensive treatment on qualitative estimates of microalbuminuria.Journal of human hypertension, 10 8
-
S.A. Douglas, L.M. Vickery-Clark, C. Louden (1994)
Acute pretreatment with carvedilol is sufficient for inhibition of neointima formation following rat carotid artery balloon angioplastyPharmacol Commun, 5
-
A. Bank, A. Kelly, Andrea Thelen, D. Kaiser, J. González-Campoy (2007)
Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus.American journal of hypertension, 20 7
-
R. Senior, Sumit Basu, C. Kinsey, Sven Schaeffer, A. Lahiri (1999)
Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction.American heart journal, 137 4 Pt 1
-
P. Omvik, P. Lund-johansen (1991)
Acute haemodynamic effects of carvedilol in essential hypertension at rest and during exercise.European heart journal, 12 6
-
R. Khattar, R. Senior, P. Soman, R. Does, A. Lahiri (2001)
Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol.American heart journal, 142 4
-
S. Hunt, William Abraham, M. Chin, A. Feldman, Gary Francis, T. Ganiats, M. Jessup, Marvin Konstam, Donna Mancini, Keith Michl, J. Oates, P. Rahko, M. Silver, L. Stevenson, C. Yancy, E. Antman, Sidney Smith, C. Adams, Jeffrey Anderson, D. Faxon, V. Fuster, J. Halperin, L. Hiratzka, A. Jacobs, Rick Nishimura, Joseph Ornato, Richard Page, Barbara Riegel (2005)
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary ArticleCirculation, 112
-
M. Patel, P. Chan, L. Betteridge, M. Schachter, P. Sever (1995)
Inhibition of Human Vascular Smooth Muscle Cell Proliferation by the Novel Multiple‐Action Antihypertensive Agent CarvedilolJournal of Cardiovascular Pharmacology, 25
-
H. Dargie (2001)
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trialThe Lancet, 357
-
M. Bristow, E. Gilbert, W. Abraham, K. Adams, M. Fowler, R. Hershberger, S. Kubo, K. Narahara, H. Ingersoll, S. Krueger, S. Young, N. Shusterman (1996)
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.Circulation, 94 11
-
M. Weber, G. Bakris, Elizabeth C, M. Iyengar, R. Fleck, D. Sica (2006)
Efficacy of a Once‐Daily Formulation of Carvedilol for the Treatment of HypertensionThe Journal of Clinical Hypertension, 8
-
M. Metra, R. Giubbini, S. Nodari, E. Boldi, M. Modena, L. Cas (2000)
Differential Effects of β-Blockers in Patients With Heart FailureCirculation, 102
-
H. Krum, J. Sackner-Bernstein, R. Goldsmith, M. Kukin, B. Schwartz, J. Penn, N. Medina, M. Yushak, Evelyn Horn, S. Katz, H. Levin, G. Neuberg, G. Delong, M. Packer (1995)
Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure.Circulation, 92 6
-
G. Cice, L. Ferrara, A. Benedetto, P. Russo, Giancarlo Marinelli, Francesco Pavese, Aldo Iacono (2001)
Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial.Journal of the American College of Cardiology, 37 2
-
Australia. (1997)
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart diseaseThe Lancet, 349
-
B. Greenberg, M. Mehra, J. Teerlink, P. Ordronneau, D. Mccollum, E. Gilbert (2006)
COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure.The American journal of cardiology, 98 7A
-
E. Ohlstein, S. Douglas, C. Sung, T. Yue, C. Louden, A. Arleth, G. Poste, R. Ruffolo, G. Feuerstein (1993)
Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury.Proceedings of the National Academy of Sciences of the United States of America, 90 13
-
G. Bakris, V. Fonseca, R. Katholi, J. McGill, F. Messerli, R. Phillips, P. Raskin, J. Wright, R. Oakes, M. Lukas, K. Anderson, D. Bell (2004)
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.JAMA, 292 18
-
R. Doughty, G. Whalley, H. Walsh, G. Gamble, J. López-Sendón, N. Sharpe (2004)
Effects of Carvedilol on Left Ventricular Remodeling After Acute Myocardial Infarction: The CAPRICORN Echo SubstudyCirculation: Journal of the American Heart Association, 109
-
G. Bakris, E. Tarka, B. Waterhouse, Michelle Goulding, A. Madan, K. Anderson, M. Sutton, Alan Miller, N. Reichek (2006)
Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile.The American journal of cardiology, 98 7A
-
R. Eggertsen, R. Sivertsson, L. Andrén, L. Hansson (1984)
Haemodynamic effects of carvedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension.Journal of hypertension, 2 5
-
Olsen Sl, E. Gilbert, D. Renlund, D. Taylor, Frank Yanowitz, M. Bristow (1995)
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.Journal of the American College of Cardiology, 25 6
-
D. Tenero, L. Henderson, Charlotte Baidoo, Angela Harter, A. Campanile, T. Danoff, D. Boyle (2006)
Pharmacokinetic properties of a new controlled-release formulation of carvedilol.The American journal of cardiology, 98 7A
-
A. Chobanian, G. Bakris, H. Black, W. Cushman, L. Green, J. Izzo, Daniel Jones, B. Materson, S. Oparil, J. Wright, E. Roccella (2003)
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.JAMA, 289 19
-
C. Dunn, A. Lea, A. Wagstaff (1997)
Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.Drugs, 54 1
-
T. Gehr, D. Tenero, D. Boyle, Y. Qian, D. Sica, N. Shusterman (1999)
The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiencyEuropean Journal of Clinical Pharmacology, 55
-
J. Refsgaard, F. Andreasen, O. Goetzsche (1999)
New aspects of endothelial dysfunction in heart failure [abstract no. 1993]Eur Heart J, 20
-
J. Sanderson, Skiva Chan, G. Yip, L. Yeung, K. Chan, K. Raymond, K. Woo (1999)
Beta-blockade in heart failure: a comparison of carvedilol with metoprolol.Journal of the American College of Cardiology, 34 5
-
J.N. Cohn, M.B. Fowler, M.R. Bristow (1997)
Safety and efficacy of carvedilol in severe heart failure: the U.S. Carvedilol Heart Failure Study GroupJ Card Fail, 3
-
L. Henderson, D. Tenero, A. Campanile, Charlotte Baidoo, T. Danoff (2007)
Ethanol Does Not Alter the Pharmacokinetic Profile of the Controlled‐release Formulation of CarvedilolThe Journal of Clinical Pharmacology, 47
-
O. Basat, S. Uçak, Selcuk Seber, E. Oztekin, Y. Altuntas (2006)
After myocardial infarction carvedilol improves insulin resistance compared to metoprololClinical Research in Cardiology, 95
-
L. Rössig, J. Haendeler, Z. Mallat, B. Hugel, J. Freyssinet, A. Tedgui, S. Dimmeler, A. Zeiher (2000)
Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol.Journal of the American College of Cardiology, 36 7
-
M. Packer, A. Coats, M. Fowler, H. Katus, H. Krum, P. Mohacsi, J. Rouleau, M. Tendera, A. Castaigne, E. Roecker, M. Schultz, D. DeMets (2001)
Effect of carvedilol on survival in severe chronic heart failure.The New England journal of medicine, 344 22
-
D. McTavish, D. Campoli-Richards, E. Sorkin (1993)
Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.Drugs, 45 2
-
J. Udelson, S. Pressler, J. Sackner-Bernstein, M. Lukas, P. Ordronneau, J. Massaro, P. Hauptman (2007)
Compliance with Once Daily Controlled Release vs Twice Daily Immediate Release Carvedilol in Patients with Heart Failure: The CASPER TrialJournal of Cardiac Failure, 13
-
R. Carreira, P. Monteiro, L. Alves, L. Providencia (2006)
Carvedilol: just another Beta-blocker or a powerful cardioprotector?Cardiovascular & hematological disorders drug targets, 6 4
-
M. Metra, R. Giubbini, S. Nodari (2000)
Differential effects of β-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilolCirculation, 102
-
W.T. Abraham, T. Tsvetkova, B.D. Lowes (1998)
Carvedilol improves renal hemodynamics in patients with chronic heart failure [abstract no. 1987]Circulation, 98
-
W. Colucci, M. Packer, M. Bristow, E. Gilbert, J. Cohn, M. Fowler, S. Krueger, R. Hershberger, B. Uretsky, J. Bowers, J. Sackner-Bernstein, S. Young, T. Holcslaw, M. Lukas (1996)
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.Circulation, 94 11
-
G. Neugebauer, W. Akpan, E. Möllendorff, P. Neubert, K. Reiff (1987)
Pharmacokinetics and Disposition of Carvedilol in HumansJournal of Cardiovascular Pharmacology, 10
-
L. Henderson, D. Tenero, Charlotte Baidoo, A. Campanile, Angela Harter, D. Boyle, T. Danoff (2006)
Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.The American journal of cardiology, 98 7A
-
P. Dandona, H. Ghanim, D. Brooks (2007)
Antioxidant activity of carvedilol in cardiovascular diseaseJournal of Hypertension, 25
-
Dr. Dupont (2005)
Effects of carvedilol on renal functionEuropean Journal of Clinical Pharmacology, 38
-
Milton Packer, George Antonopoulos, Jesse Berlin, Jesse Chittams, M. Konstam, J. Udelson (2001)
Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis.American heart journal, 141 6
-
M. Weber, D. Sica, E. Tarka, M. Iyengar, R. Fleck, G. Bakris (2006)
Controlled-release carvedilol in the treatment of essential hypertension.The American journal of cardiology, 98 7A
-
M. Packer, W. Colucci, J. Sackner-Bernstein, C. Liang, D. Goldscher, I. Freeman, M. Kukin, V. Kinhal, J. Udelson, M. Klapholz, S. Gottlieb, D. Pearle, R. Cody, J. Gregory, N. Kantrowitz, T. LeJemtel, S. Young, M. Lukas, N. Shusterman (1996)
Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart FailureCirculation, 94
- Publisher
- Springer Journals
- Copyright
- Copyright © 2008 by Adis Data Information BV
- Subject
- Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
- ISSN
- 1175-3277
- eISSN
- 1179-187X
- DOI
- 10.2165/00129784-200808040-00007
- pmid
- 18690761
- Publisher site
- See Article on Publisher Site
Abstract
▴ A new once-daily controlled-release (CR) capsule formulation of the nonselective β- and α1-adrenoceptor antagonist carvedilol is now available for use in the treatment of essential hypertension, heart failure (HF), and left ventricular dysfunction following myocardial infarction (MI).
Journal
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 17, 2012